Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
Findings to Focus on Ability of Immunoscore IC Test to Predict Efficacy of Immune Checkpoint Inhibitors in Patients with NSCLC
“The findings being presented at the ASCO annual meeting expand the performance and utility data for our clinical tests, while demonstrating the role our novel immuno-oncology offerings may play in advancing new frontiers in personalized medicine,” said
The following abstracts will be shared as part of the 2022 ASCO Annual Meeting:
Title: |
Efficacy of anti-PD1/PD-L1 immunotherapy in non–small cell lung cancer is dependent upon Immunoscore IC CD8 and PD-L1 status. |
Presenter: |
|
Date/Time: |
|
Abstract #: |
2509 |
Format: |
Oral Presentation ( |
Session: |
Clinical Science Symposium Looking Everywhere for Determinants of Benefit From Immunotherapy |
|
|
|
|
Title: |
International validation of the Immunoscore-biopsy (ISB) to guide selection and monitoring of patients treated with watch-and-wait (WW) strategy for rectal cancer. |
Presenter: |
|
Date/Time: |
|
Abstract #: |
3517 (Poster #311) |
Format: |
Poster Discussion |
Session: |
Gastrointestinal Cancer—Colorectal and Anal |
|
|
|
|
Title: |
Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). |
Presenter: |
|
Date/Time: |
|
Abstract #: |
7565 (Poster #218) |
Format: |
Poster |
Session: |
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
|
|
|
|
Title: |
Interim analysis of the phase II AVETUXIRI trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC). |
Presenter: |
|
Date/Time: |
|
Abstract #: |
3595 (Poster #389) |
Format: |
Poster |
Session: |
Gastrointestinal Cancer—Colorectal and Anal |
|
|
|
|
Title: |
Treatment patterns and outcomes in prostate cancer patients tested with Decipher in SEER. |
First Author: |
Nicholas G. Zaorsky, M.D., M.S., |
Abstract #: |
e17006 |
Format: |
Publication Only |
|
|
|
|
Title: |
Molecular profiling of dedicated lung cancer biopsy tissue sample collected at time of diagnostic bronchoscopy. |
First Author: |
|
Abstract #: |
e20587 |
Format: |
Publication Only |
About
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests and immuno-oncology offerings. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," “suggest,” "may," "will" “prospective” and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. An example of a forward-looking statement includes, among others, that the Envisia Genomic Classifier is designed to help physicians more accurately, quickly and confidently diagnose IPF. Additional factors that may impact these forward-looking statements can be found under the caption “Risk Factors” in our Annual Report on Form 10-K filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512005368/en/
Investors:
Director, Investor Relations
investors@veracyte.com
619-393-1545
Media:
Vice President of
tracy.morris@veracyte.com
650-380-4413
Source: